hero image

Biogen to Present at the Cowen 40th Annual Health Care Conference

February 24, 2020 Investor Relations

Cambridge, MA, - - Biogen Inc.  (Nasdaq: BIIB) announced today that it will present at the Cowen 40th Annual Health Care Conference. The webcast will be live on Monday, March 2, at 11:20 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors.  An archived version of the webcast will be available following the presentation.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
  
Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442

thumb
April 19, 2021
18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research and Therapy

Lecanemab Phase 3 Clarity AD Clinical Trial Completed Enrollment TOKYO , April 19, 2021 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts , CEO: Michel Vounatsos , "Biogen") today

thumb
April 19, 2021
Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients

Initial findings from the DEVOTE study suggest no new safety concerns and support continued development of a higher dose of SPINRAZA ® (nusinersen) Additional research reinforces the potential of biomarkers and highlights new digital tools that may help guide future treatment approaches and